Frontotemporal dementia (FTD) is a group of clinically heterogeneous neurodegenerative diseases that include Frontotemporal Dementia with Parkinsonism linked to chromosome 17 (FTDP17), progressive supranuclear palsy, corticobasal degeneration, Pick's disease, and FTD associated with motor neuron disease/amyotrophic lateral sclerosis. All these diseases present similar neuropathological findings, the most striking of which are neuronal loss and gliosis predominantly in frontal and/or temporal cortices, with subcortical nuclei, brain stem nuclei and spinal cord anterior and/or posterior horns also frequently affected. Moreover, one of the hallmarks of this group of diseases are intracytoplasmic inclusions called neurofibrillary tangles (NFT). They are immunopositive for the protein tau in a hyperphosphorylated state and are found in neurons as well as in glial cells. The role ABSTRACT: Objective: Frontotemporal dementia is a neurodegenerative disease affecting mostly the frontal and/or temporal lobes, with neuronal loss and intraneuronal and/or intraglial inclusions composed of hyperphosphorylated microtubule-associated protein tau and ubiquitin. Missense and splice site mutations in the TAU gene have been identified in approximately 15% of all frontotemporal dementia cases. In this study, we evaluated the involvement of mutations in the TAU gene in development of frontotemporal dementia phenotype in patients of French or English Canadian origins. Methods: Fourteen patients with frontotemporal dementia phenotype and 98 normal controls were recruited for the study. The TAU gene was screened by sequencing and denaturing high performance liquid chromatography. Results: No mutations, except some new polymorphisms, were detected in the TAU gene of these patients. One polymorphism, however, may play a role in pathogenesis. Conclusion: Our results agree with previous work suggesting that mutations in this gene are not a frequent cause of the frontotemporal dementia phenotype in Canadian patients.
microtubule polymerization and stability.Tau is specific to axons in which the microtubules play an important role in cell traffic and maintenance of the shape of the axon. 1 Glia (astrocytes and oligodendrocytes) also express this gene but the consequence of tau aggregates in these cells is still unclear. 1, 2 Tau is expressed as six isoforms, produced by alternative splicing of different exons. One half of the isoforms contain the exon 10, while the other half do not. This exon encodes for one of the four microtubule-binding domains of the protein, which are composed of repetitive amino acid motifs. Three of the isoforms contain four such domains, while the other three contain three domains. The two types of the isoforms are designated 4R and 3R. The central nervous system (CNS) ratio of 4R to 3R is close to one, but slight variations are detected in d i fferent parts of the CNS. 1 -4 Baker et al 5 identified a series of polymorphisms spread through the MAPT gene. These polymorphisms constitute two extended haplotypes that cover the gene. In a total of approximately 200 unrelated Caucasian individuals, no recombination between the two haplotypes was detected. This suggests that the establishment of the two haplotypes was an ancient event and that either recombination was suppressed in this region, or recombination was selected against. The more common haplotype is designated H1 (also A), and the less common one -H2 (also B). [5] [6] [7] About 40% of FTD cases are familial and in approximately 40% of familial cases mutations in the TAU gene were detected. 8 More than 20 different mutations segregating with the disease phenotype have been reported. 1, 2 The mutations are almost exclusively grouped in and around exons 9, 10, and 12, which encode for the four microtubule-binding domains, and exon 13. 1 One half of those are missense mutations apparently reducing t a u 's capacity to bind to microtubules and stabilize them, whereas the other half, clustered in and around exon 10, seem to affect the alternative splicing of this exon and result in this exon being more frequently retained in TAU transcripts. 1, 2, 4, [8] [9] [10] This apparently changes the normal 3R/4R isoform ratio of tau, which a ffects the microtubule-binding capacity of tau. As a consequence, all mutations seem to result in an increase of unbound tau in the cytoplasm of neurons (and/or glia), 1, 11, 12 which is thought to be the primary event in the formation of the intraneuronal and/or intraglial tau aggregates. 13 
METHODS AND MATERIALS

Subjects
All samples were obtained after approval of the Ethics Committee of the Douglas Hospital, Québec, Canada. A total of 10 unrelated patients of French Canadian origin and four unrelated patients of English Canadian origin, with different subtypes of FTD, were recruited for the study (Table 1) . Patients were either from Québec or Ontario, Canada. Six patients had a familial history (i.e. presence of at least one other affected family member). Final diagnosis of dementia-amyotrophic lateral sclerosis (ALS) was established clinically in four patients, two of whom had family history of ALS and one, of FTD-ALS. In the other 10 patients, the clinical diagnosis was that of a dementia (one patient with dementia-ALS). Their final diagnosis of FTD was established on neuropathology by an expert neuropathologist (Y.R.) using the Lund and Manchester Groups criteria for FTD 14 (Table 2 ). The neuropathological examination revealed: two cases of classical FTD, one of which had a primary progressive aphasia; two cases of progressive supranuclear palsy, one of which had a family history; one case of corticobasal degeneration; and five less well-defined cases for which Alzheimer's type dementia was definitely excluded. These were: two unspecified dementias (both with family history), one dementing syndrome with severe ataxia and dysartria, and two cases of cerebral senile changes with mental confusion, one of THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES 364 which was the case clinically diagnosed with ALS. Ninety-eight normal controls from the same age group and geographic area were recruited for the study. For the 10 patients examined neuropathologically as well as three normal controls, DNA was obtained from frozen brain tissue (cerebellum) using standard methods. For the other normal controls, as well as the other four patients, DNA was extracted from whole blood using standard procedures.
Genetic studies
Only exons expressed in the CNS (TAU genomic sequence at http//genome.UCSC.edu), i.e. exons 1, 2, 3, 4, 5, 7, 9, 10, 11, 12, and 13 were screened. Primers and polymerase chain reaction (PCR) amplification conditions were described elsewhere. 15 Each of the amplicons -exons and their neighbouring intron regions -were analyzed by denaturing high performance liquid chromatography on the WAVE DNAFragment Analysis System ( Transgenomics, Omaha, USA). This method allows the detection of heteroduplexes (annealing of two DNAstrands with one to several base pair mismatch because of the presence of different alleles) in a PCR product. It is based on the fact that the melting temperature for a heteroduplex is lower than that for a homoduplex (two perfectly annealed DNA strands). So, at a given melting temperature, the heteroduplex will denaturate earlier in time. The presence of DNA in elution is then detected by the apparatus, and the presence of the heteroduplex will be registered as a separate peak (also called variant) of the UV light absorption. Samples with faint and strong variants detected on denaturing high performance liquid chromatography were subsequently sequenced using the big dye terminator chemistry on an ABI 3700 sequencer (Applied Biosystems) using the same primers as for the PCR. Sequence alignments were performed using SeqMan II software from DNASTAR Inc. For direct sequencing, PCR products were purified from an agarose gel using Qiax II Gel Extraction Kit (Qiagen) and the Thermo Sequenase Radiolabeled Terminator Cycle Sequencing Kit ( 33 Plabeled) from USB was used. Results of direct sequencing were read on the BIOMax film from Kodak.
An RT-PCR was performed to evaluate the 4R/3R tau ratios. The positions of the primers used are presented on the Figure 1 and their sequences are: CCCGCACCCCGTCCCTTCC (forward primer) and T TA C T T C C A C C T G G C C A C C T C C T G (reverse primer). The two following quantitative PCRs were done with reduced numbers of cycles, 23 and 27, so to avoid erasing differences between the two isoforms by an overamplification.
RESULTS
A total of 10 variants were detected in this study ( Table 3) . Some of the variants have already been reported in literature as TAU polymorphisms also present in the healthy population (the 255 G to A variant in exon 9, also found in one normal control in this study, and the G to A substitution situated at +29 of the intron 10 8, 15 ). Two of the variants were not previously reported and thus were considered as new polymorphisms. The C to T substitution 40 base pairs inside the intron 9 was also present in two normal controls, and for that reason the possibility that it is a pathogenic mutation was excluded. The A to T substitution 3,810 base pairs inside the intron 3 is located 94 bases pairs before the exon 4.
The possibility that it is a pathogenic mutation was ruled out based on two reasons: (1) it does not disrupt the splicing consensus motives for either the exon 3 or 4; (2) while the A is conserved in the mouse, it is not in the rat, which makes it less likely to be functionally important.
Six sequence variations, that are part of the haplotype H2, were seen only in two of the patients. 6 These patients were therefore carriers of the haplotype H2. They were also the same ones that presented the A to T substitution 3,810 base pairs inside the intron 3, which makes it possible that this variant is a previously undetected part of the haplotype H2.
However, the G to A change at +34 of the intron 11, which normally would be found on the haplotype H2, 6 was not found in these two subjects. They both had the genotype G/G (usually found on the haplotype H1).
The G to A substitution is located 29 base pairs inside the intron 10 and the G is conserved in both mouse and rat. To determine if the presence of the A allele affects the alternative splicing of this exon, a quantitative PCR for the cDNA region flanking the exon 10 ( Figure 1 ) was performed in order to estimate the relative abundances of the 4R and 3R isoforms of tau. The quantitative PCR did not show any difference in abundances between the 4R and 3R isoformes in the patient with this variant (Figure 2 ).
DISCUSSION
It has become clear that, despite the importance of the discovery of TAU mutations as a cause of the FTD phenotype, mutations in this gene do not explain the majority of cases of FTD (approximately 15%) and not even the majority of familial cases (approximately 40%). 15, 16 Our results support this view by showing a lack of disease phenotype-associated mutations in the TAU gene in a cohort of French Canadian and English Canadian patients with the FTD phenotype. Indeed, it is likely that this phenotype in our patients is caused by different and/or yet unknown molecular pathological processes. The identification of additional genes responsible for FTD is critical in order to understand the full spectrum of pathological phenomena evolving in the CNS of FTD patients. A number of candidate genes have been proposed, including cytoplasmic kinases such as Cdk5 and MAPT, 17, 18 and/or phosphatases, 17 considering that tau is found in a hyperphosphorylated state in the NFT/inclusions. In addition, candidate chromosome loci include a 9q21-22 locus linked to the FTD-ALS phenotype 19 and a 3p11.1-q11.2 locus (OMIM #600795) linked to an unspecified dementia phenotype.
This study allowed discovery of two new polymorphisms in the TAU gene, without apparent role in the disease. One of the new variants, the A to T in the intron 3, was not detected in normal controls. However, it is not conserved in the rat and it does not disrupt any known splice site; it was also detected in the same two individuals that were carriers of the H2 haplotype. It is thus possible that this polymorphism is a part of the H2 haplotype and that it may simply have been missed by previous studies.
The absence of one previously published element of haplotype H2, the A at the position 34 in the intron 11 (G in case of the haplotype H1), in the two patients clearly segregating the H2 haplotype, may be explained in two different ways. There may have occurred a recombination between the two haplotypes, which previously were believed to never recombine. [5] [6] [7] This is possible given that the variant is at the end of the haplotype. Secondly, because the two patients are both of the French Canadian origin, the A allele may have changed to a G de novo in a common H2 haplotype bearing ancestor.
The G to A substitution situated at +29 in intron 10 was previously described as a polymorphism, because it does not change the 4R/3R tau isoform ratios, 8 which was also confirmed in our study (Figure 2 ). It was however present only in affected subjects in our study; and it is also conserved in both the mouse and the rat. This variant might therefore be pathogenic by some yet undetermined mechanisms and may even be causing the FTD-ALS phenotype, since the patient with the variant had a clinical diagnosis of ALS complicated with dementia. Further studies are needed to resolve this question.
